{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:55Z","timestamp":1791357295282,"version":"4.3.1"},"reference-count":37,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T00:00:00Z","timestamp":1486598400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T00:00:00Z","timestamp":1486598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1002\/jcph.873","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T09:13:02Z","timestamp":1486631582000},"page":"823-829","source":"Crossref","is-referenced-by-count":9,"title":["Causative Drugs of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Israel"],"prefix":"10.1002","volume":"57","author":[{"given":"Nicola","family":"Maggio","sequence":"first","affiliation":[{"name":"Department of Neurology; Sheba Medical Center; Tel Hashomer Israel"},{"name":"Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Firer","sequence":"additional","affiliation":[{"name":"Institute for Drug Research, School of Pharmacy; The Hebrew University of Jerusalem; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Zaid","sequence":"additional","affiliation":[{"name":"Institute for Drug Research, School of Pharmacy; The Hebrew University of Jerusalem; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Bederovsky","sequence":"additional","affiliation":[{"name":"Institute for Drug Research, School of Pharmacy; The Hebrew University of Jerusalem; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Aboukaoud","sequence":"additional","affiliation":[{"name":"Institute for Drug Research, School of Pharmacy; The Hebrew University of Jerusalem; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Revital","family":"Gandelman-Marton","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv Israel"},{"name":"Department of Neurology; Assaf Harofeh Medical Center; Zerifin Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Noyman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology; Soroka Medical Center, Ben Gurion University of the Negev; Beer Sheva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Ekstein","sequence":"additional","affiliation":[{"name":"Department of Neurology; Agnes Ginges Center for Human Neurogenetics; Hadassah-Hebrew University Medical Center; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Blatt","sequence":"additional","affiliation":[{"name":"Department of Neurology; Sheba Medical Center; Tel Hashomer Israel"},{"name":"Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Marom","sequence":"additional","affiliation":[{"name":"Pharmaceutical Division; Israel Ministry of Health; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Schwartzberg","sequence":"additional","affiliation":[{"name":"Pharmaceutical Division; Israel Ministry of Health; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Israel","sequence":"additional","affiliation":[{"name":"Tissue Typing Unit; Hadassah-Hebrew University Medical Center; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arieh","family":"Ingber","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Hadassah-Hebrew University Medical Center; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaim","family":"Brautbar","sequence":"additional","affiliation":[{"name":"Tissue Typing Unit; Hadassah-Hebrew University Medical Center; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eyal","sequence":"additional","affiliation":[{"name":"Institute for Drug Research, School of Pharmacy; The Hebrew University of Jerusalem; Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"10.1002\/jcph.873-BIB0001|jcph873-cit-0001","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1002\/jcph.873-BIB0002|jcph873-cit-0002","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1002\/jcph.873-BIB0003|jcph873-cit-0003","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1002\/jcph.873-BIB0004|jcph873-cit-0004","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jcph.873-BIB0005|jcph873-cit-0005","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1528-1157.1999.tb00807.x","article-title":"Lamotrigine-associated rash: risk\/benefit considerations in adults and children","volume":"40","author":"Guberman","year":"1999","journal-title":"Epilepsia"},{"key":"10.1002\/jcph.873-BIB0006|jcph873-cit-0006","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1002\/jcph.873-BIB0007|jcph873-cit-0007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bcp.12749","article-title":"Classifying ADRs-does dose matter?","volume":"81","author":"Phillips","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/jcph.873-BIB0008|jcph873-cit-0008","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1002\/jcph.873-BIB0009|jcph873-cit-0009","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/epi.12564","article-title":"Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions","volume":"55","author":"Amstutz","year":"2014","journal-title":"Epilepsia"},{"key":"10.1002\/jcph.873-BIB0010|jcph873-cit-0010","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1002\/jcph.873-BIB0011|jcph873-cit-0011","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1002\/jcph.873-BIB0012|jcph873-cit-0012","unstructured":"US Food and Drug Administration Table of Pharmacogenomic Biomarkers in Drug Labeling http:\/\/www.fda.gov\/Drugs\/ScienceResearch\/ResearchAreas\/Pharmacogenetics\/ucm083378.htm"},{"key":"10.1002\/jcph.873-BIB0013|jcph873-cit-0013","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jcph.873-BIB0014|jcph873-cit-0014","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1750-1172-6-52","article-title":"Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe","volume":"6","author":"G\u00e9nin","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1002\/jcph.873-BIB0015|jcph873-cit-0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jcph.873-BIB0016|jcph873-cit-0016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1002\/jcph.873-BIB0017|jcph873-cit-0017","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1111\/epi.13498","article-title":"Genetic risk factors for antiepileptic drug-induced hypersensitivity reactions in Israeli populations","volume":"57","author":"Israel","year":"2016","journal-title":"Epilepsia"},{"key":"10.1002\/jcph.873-BIB0018|jcph873-cit-0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1002\/jcph.873-BIB0019|jcph873-cit-0019","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1002\/jcph.873-BIB0020|jcph873-cit-0020","unstructured":"Central Bureau of Statistics 2016 http:\/\/www.cbs.gov.il\/www\/hodaot2016n\/11_16_134e.pdf"},{"key":"10.1002\/jcph.873-BIB0021|jcph873-cit-0021","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0198-8859(99)00043-9","article-title":"Molecular analysis of HLA class II polymorphisms among different ethnic groups in Israel","volume":"60","author":"Amar","year":"1999","journal-title":"Hum Immunol"},{"key":"10.1002\/jcph.873-BIB0022|jcph873-cit-0022","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1399-0039.1978.tb01255.x","article-title":"HLA polymorphism in Israel. 9. An overall comparative analysis","volume":"11","author":"Bonn\u00e9-Tamir","year":"1978","journal-title":"Tissue Antigens"},{"key":"10.1002\/jcph.873-BIB0023|jcph873-cit-0023","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baw069","article-title":"A web resource for mining HLA associations with adverse drug reactions: HLA-ADR","author":"Ghattaoraya","year":"2016","journal-title":"Database (Oxford)"},{"key":"10.1002\/jcph.873-BIB0024|jcph873-cit-0024","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1126\/science.1243518","article-title":"A genetic atlas of human admixture history","volume":"343","author":"Hellenthal","year":"2014","journal-title":"Science"},{"key":"10.1002\/jcph.873-BIB0025|jcph873-cit-0025","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1399-0039.2010.01549.x","article-title":"Genetic differentiation of Jewish populations","volume":"76","author":"Klitz","year":"2010","journal-title":"Tissue Antigens"},{"key":"10.1002\/jcph.873-BIB0026|jcph873-cit-0026","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.yebeh.2016.05.004","article-title":"Utilization of antiepileptic drugs in Israel","volume":"61","author":"Berman","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1002\/jcph.873-BIB0027|jcph873-cit-0027","volume-title":"Drug Consumption in Norway 2010-2014","author":"Sakshaug","year":"2015"},{"key":"10.1002\/jcph.873-BIB0028|jcph873-cit-0028","unstructured":"Finnish Statistics on Medicines Helsinki Finnish Medicines Agency Fimea and Social Insurance Institution 2015 https:\/\/www.fimea.fi\/web\/en\/databases_and_registeries\/consumption\/finnish_statistics_on_medicines"},{"key":"10.1002\/jcph.873-BIB0029|jcph873-cit-0029","first-page":"607","volume-title":"Immunobiology of the Human MHC: Proceedings of the 13th International Histocompatibility Workshop and Conference","author":"Gazit","year":"2006"},{"key":"10.1002\/jcph.873-BIB0030|jcph873-cit-0030","unstructured":"National Marrow Donor Program (US) Jewish high-resolution haplotype frequencies https:\/\/bioinformatics.bethematchclinical.org\/hla-resources\/haplotype-frequencies\/jewish-high-resolution-haplotype-frequencies\/"},{"key":"10.1002\/jcph.873-BIB0031|jcph873-cit-0031","first-page":"604","volume-title":"Immunobiology of the Human MHC: Proceedings of the 13th International Histocompatibility Workshop and Conference","author":"Brautbar","year":"2006"},{"key":"10.1002\/jcph.873-BIB0032|jcph873-cit-0032","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.161","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update","volume":"99","author":"Saito","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jcph.873-BIB0033|jcph873-cit-0033","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2174\/157488610791698299","article-title":"Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population","volume":"5","author":"Efrati","year":"2010","journal-title":"Curr Drug Saf"},{"key":"10.1002\/jcph.873-BIB0034|jcph873-cit-0034","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lfs.2005.04.049","article-title":"Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations","volume":"78","author":"Nakai","year":"2005","journal-title":"Life Sci"},{"key":"10.1002\/jcph.873-BIB0035|jcph873-cit-0035","unstructured":"The Israel Ministry of Health The Israel Drug Registry http:\/\/www.old.health.gov.il\/units\/pharmacy\/trufot\/index.asp?safa=e"},{"key":"10.1002\/jcph.873-BIB0036|jcph873-cit-0036","unstructured":"Lamictal label http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020241s045s051lbl.pdf"},{"key":"10.1002\/jcph.873-BIB0037|jcph873-cit-0037","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcph.873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:04:08Z","timestamp":1657803848000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.873"}},"subtitle":["Journal of Clinical Pharmacology"],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.873","archive":["Portico"],"relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}